Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherBrowse by ChannelAbout the NetworkJoin the NetworkProductsSub-MenuProducts OverviewBlog ProBlog PlusBlog PremierMicrositeSyndication PortalsAbout UsContactSubscribeSupport
Book a Demo
Search
Close

Another Round of Notice of Penalty Offenses—The FTC Targets Health Claims

By Amanda Beane, Tim Carter & Nathan Kosnoff on May 1, 2023
Email this postTweet this postLike this postShare this post on LinkedIn

Key updates:

  • Under its Penalty Offense Authority, the Federal Trade Commission (FTC) warned almost 700 marketers with a Notice of Penalty Offenses (Notice) that certain advertising claims must be proven or substantiated with reliable evidence, especially those related to health products, or they may face civil penalties.
  • Advertisers should have a reasonable basis for health claims, including complying with recognized scientific standards when making claims about the effectiveness of their products in curing, mitigating, or treating significant conditions such as cancer or heart disease.
  • The Notice comes on the heels of the FTC updates to Health Products Compliance Guidance (the Health Guides) and indicates the FTC continues to scrutinize health claims.

The Notice was sent to companies involved in the marketing of over-the-counter drugs, homeopathic products, dietary supplements, or health foods. The Notice does not establish new rules or guidance by the FTC, but creates a path for the FTC to more easily assess penalties if companies make certain claims without adequate substantiation. The FTC used the same tactic near the end of 2021, issuing hundreds of Notices to companies using influencers and endorsers—and referenced and included the influencer and endorser notice with this one.

The Notice details specific actionable practices including:

  • Failure to provide a reasonable basis for objective product claims.
  • Failure to provide competent and reliable scientific evidence for health or safety claims.
  • Failure to undertake well-controlled human clinical studies to back up claims about curing, mitigating, or treating serious diseases.
  • Falsifying scientific validity or misrepresenting the type of substantiation for a claim.

Advertisers of health-related products should be sure to carefully review and understand the FTC’s recently issued updates to the Health Products Compliance Guidance (the Health Guides). The Health Guides reflect a significant expansion of the FTC’s prior guidance concerning advertising for health-related products. See our previous blog post for more detail on the changes to the health guidelines.

Photo of Amanda Beane Amanda Beane

Amanda Beane serves as co-chair of the Advertising, Marketing & Promotions practice.

Read more about Amanda BeaneEmail
Photo of Tim Carter Tim Carter

Tim Carter represents, counsels, and defends clients in intellectual property (IP), media, advertising, unfair competition, and consumer protection matters.

Read more about Tim CarterEmail
Photo of Nathan Kosnoff Nathan Kosnoff

Nathan Kosnoff has experience working on a broad range of matters, including intellectual property and trademark disputes, antitrust, construction defect litigation, campaign finance law, and government and internal investigations.

Read more about Nathan KosnoffEmail
  • Posted in:
    Corporate & Commercial
  • Blog:
    Consumer Protection Review
  • Organization:
    Perkins Coie LLP
  • Article: View Original Source

LexBlog, Inc. logo
Facebook LinkedIn Twitter RSS
Real Lawyers
99 Park Row
  • About LexBlog
  • Careers
  • Press
  • Contact LexBlog
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Terms of Service
  • RSS Terms of Service
  • Products
  • Blog Pro
  • Blog Plus
  • Blog Premier
  • Microsite
  • Syndication Portals
  • LexBlog Community
  • Resource Center
  • 1-800-913-0988
  • Submit a Request
  • Support Center
  • System Status
  • Resource Center
  • Blogging 101

New to the Network

  • Beyond the First 100 Days
  • In the Legal Interest
  • Cooking with SALT
  • The Fiduciary Litigator
  • CCN Mexico Report™
Copyright © 2025, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo